Profound Medical Corp · TSX:PRN
Profound Medical — Investor Presentation (November 2025)
32 slides from Profound Medical's investor presentation, November 2025
Slide 1: Precision Surgery without incision
Precision Surgery without incision It’s happening! © 2025 PROFOUND MEDICAL CORP. CORPORATE PRESENTATION NASDAQ: PROF | TSX: PRN
Slide 2: Forward-Looking Information
Forward-Looking Information 2 Certain statements in this presentation may contain certain information that is “forward-looking information” or “forward-looking statements” within the meaning of applicable securities laws with respect to Profound Medical Corp. (“Profound” or the “Company”). Such stat
Slide 3: Market & Industry Data
3 NASDAQ: PROF | TSX: PRN Market & Industry Data Market data and industry forecasts contained in this presentation have been obtained from industry publications, various publicly available third-party sources and subscription-based reports as well as from management’s good faith estimates, which are
Slide 4: Grow Topline with TULSA-PRO & Opportunistically Advance Sonalleve
Grow Topline with TULSA-PRO & Opportunistically Advance 4 Sonalleve NASDAQ: PROF | TSX: PRN Primary Investment Incremental Investment CORPORATE PRESENTATION Precision Ablative treatment of Precision Ablative treatment of Prostate Cancer (“PCa”), Benign Adenomyosis and Uterine Fibroid Prostatic Hyper
Slide 5: CORPORATE PRESENTATION
5 NASDAQ: PROF | TSX: PRN • Precision of MR imaging and thermography • Sound absorption to heat tissue only to kill temperature 55-57C (no charring no boiling) • AI-driven treatment plan to minimize side effects • Suitable for whole-gland, near-whole-gland or even focal treatment CORPORATE PRESENTAT
Slide 6: Prostate Cancer: The Unmet Need
Prostate Cancer: The Unmet Need 6 Over 300,000 U.S. PCa cases Prostatectomy Outcomes: each year NASDAQ: PROF | TSX: PRN Prospective Multicenter Comparison of Open vs Robotic Prostatectomy: The PROST-QA/RP2 Consortium Peter Chang, Andrew A. Wagner, Meredith M. Regan et al. Radical Prostatectomy Radia
Slide 7: TULSA-PRO is a Groundbreaking Technology Platform
TULSA-PRO is a Groundbreaking Technology Platform 7 There are 3-main subsystems of the technology NASDAQ: PROF | TSX: PRN Real-time MRI Robotics Thermal energy 1 2 3 AI Software & Thermography from ultrasound ® CORPORATE PRESENTATION • Thermal Boost • Contouring Assistant • Alignment Assistant • Vol
Slide 8: The TULSA Procedure
The TULSA Procedure (Performed with the TULSA-PRO System) 8 NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION https://profoundmedical.com/wp-content/uploads/2025/05/106885B-TULSA-PRO-3D-ANIMATION-compressed.mp4
Slide 9: TULSA For Whole-Gland or Partial/Focal Ablation
TULSA For Whole-Gland or Partial/Focal Ablation 9 Older whole-gland TULSA whole-gland or Focal therapies, typically NASDAQ: PROF | TSX: PRN treatments partial/focal procedure treat <25% of gland Robotic Laparoscopic CORPORATE PRESENTATION Prostatectomy High Intensity Focused Ultrasound, HIFU Whole-g
Slide 10: TULSA Technology's Unrivalled Flexibility Allows Ability to Address PCa and a Segment of BPH
TULSA Technology’s Unrivalled Flexibility Allows Ability to 10 Address PCa and a Segment of BPH NASDAQ: PROF | TSX: PRN NE X T TA RG PCa E T Whole-Gland (~80% of patients): • Robotic Prostatectomy (>20 yrs) BPH • Radiation (>20 yrs; • Waterjet ablation (5 yrs) CORPORATE PRESENTATION although now rob
Slide 11: TULSA-PRO U.S. Market Opportunity
TULSA-PRO U.S. Market Opportunity 11 PCa BPH / Hybrid NASDAQ: PROF | TSX: PRN Overgrow transition zone Cancerous tissue CORPORATE PRESENTATION ~400,000 1 ~200,000 1 Addressable Addressable Cases Annually Cases Annually Average Average ~$8,000 ~$8,000 2 2 Procedure Price Procedure Price $1.6 Billion
Slide 12: 70+ Peer-Reviewed Publications & 200+ Conference Presentations
70+ Peer-Reviewed Publications & 200+ Conference Presentations 12 Clinical Evidence in Unrivaled Variety of Prostate Indications Partial Gland Ablation Whole Gland Ablation NASDAQ: PROF | TSX: PRN Benign Organ Confined Prostate Cancer Salvage / Palliative Large prostate BPH, Hybrids with low grade L
Slide 13: CAPTAIN: Customized Ablation with TULSA vs. Prostatectomy
13 CAPTAIN (NCT05027477) NASDAQ: PROF | TSX: PRN Customized Ablation with TULSA vs. Prostatectomy in Intermediate-Risk Prostate Cancer CAPTAIN is an audacious trial that would be the first to generate Level 1 evidence demonstrating superior safety and non-inferior efficacy of ablative therapy vs. RP
Slide 14: CAPTAIN Trial Data: Eliminates Blood Loss & Overnight Stay
CAPTAIN TRIAL DATA: TULSA-PRO Eliminates Blood Loss & 14 Overnight Stay for the Patient & Hospital NASDAQ: PROF | TSX: PRN From less blood loss to From shorter length of stay to No blood loss No overnight stay CORPORATE PRESENTATION p < 0.001 Dinner p < 0.001 0 1 2 Length of stay (days) Treatment Me
Slide 15: CAPTAIN Trial Data: Patients in Better Overall Health After Treatment
CAPTAIN TRIAL DATA: TULSA-PRO Patients are in 15 Better Overall Health After Treatment NASDAQ: PROF | TSX: PRN Significantly better overall health during first month post treatment Change in EQ-5D-5L VAS overall health score after treatment TULSA Patients: Significantly less deterioration in Change
Slide 16: Established & Increasing Clinical Evidence Continue to Validate TULSA
Established & Increasing Clinical Evidence Continue to Validate TULSA 16 Review of all prostate ultrasound (and IRE) ablation publications for the U.S. NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION
Slide 17: TULSA-PRO Utilization Trends: Q2-2025
TULSA-PRO Utilization Trends: 17 Q2-2025 Indication NASDAQ: PROF | TSX: PRN 0% 20% 40% 60% 80% 100% • 99% of patients treated PCa, of those PCa PCa + BPH Salvage BPH 17% had low grade PCa and BPH Ablation • 48% of ablations were whole-gland, with the remainder sub-total but more than 0% 20% 40% 60%
Slide 18: AI is Here To Stay, is in its Infancy, and Growing Fast
AI is Here To Stay, is in its 18 Infancy, and Growing Fast NASDAQ: PROF | TSX: PRN Contouring Assistant May 2024 Contouring Assistant 1.0 was non-inferior to manual segmentations by expert urologists and radiologists CORPORATE PRESENTATION June 2025 Contouring Assistant 2.0 superior to urologists de
Slide 19: TULSA's Primary Competitive Positioning is Vs. Robotic Surgery
TULSA’s Primary Competitive Positioning is Vs. Robotic Surgery 19 1. Interventional MRI (iMRI) Movement has Started Short-term: TULSA compatible with ~5,000 installed MRs in the U.S.: less than ~200 needed to reach profitability NASDAQ: PROF | TSX: PRN Medium-term: TULSA + Siemens designed MRs for i
Slide 20: Comparative Procedure Summary - 2025 Final Rule
Comparative Procedure Summary- 20 2025 Final Rule (National Average) TULSA Procedure Strongly Positioned Against Other Options NASDAQ: PROF | TSX: PRN 2025 Non- 2025 Non- CPT Global 2025 Hospital 2025 ASC Facility OBL Facility OBL Procedure 2025 APC Level Code Period HOPD Payment Payment RVU Dollar
Slide 21: Reimbursement - Physician Fee 2025
Reimbursement- Physician Fee (Facility: HOPD & ASC) 2025 21 90-Day F/U, Total RVU w 90 Total Payment NASDAQ: PROF | TSX: PRN Procedure Global Period Procedure RVUs Billable* Days* (Ntl Avg)^ TULSA Complete Procedure 0 Days 17.91 10.49 28.40 $918.74 CPT Code [55882] TULSA Device Management 0 Days 6.4
Slide 22: 2000–2024: Building a High-Quality Installed Base & Market Leadership
2000–2024: Building a High-Quality Installed Base & Market 22 Leadership NASDAQ: PROF | TSX: PRN 1 Market Entry Strategy 2 Top-Tier Hospitals • Focus on opinion leaders, early adopters, Opinion leaders, validation, reimbursement imaging centers cost calculations, publications • Service provider busi
Slide 23: TULSA-PRO Growth Strategy
TULSA-PRO Growth Strategy 23 NASDAQ: PROF | TSX: PRN SHORT-TERM MID-TERM LONG-TERM Path to Profitability Exponential Growth Sustained Leadership 200 TULSA programs using Complete solution, Fully integrated TULSA + iMRI existing MR installed base advanced workflow platform positioned as the → ~$85M a
Slide 24: Marketing Focus – 2025/2026
Marketing Focus – 2025/2026 24 Patient Education NASDAQ: PROF | TSX: PRN • Leanord Wheeler as brand ambassador. Has already done multiple Tv spots, routinely receiving >30,000 views/event • tulsaprocedure.com website being revamped to not only educate patients but also track patients through treatme
Slide 25: Putting it together – MR centered prostate care pathway is here
Putting it together – MR centered prostate care pathway is here 25 Use of MRI to diagnose & biopsy a patient has increased based upon positive guideline recommendations NASDAQ: PROF | TSX: PRN mpMR bpMR Diagnostic 1 Prostate screening – men 50 years of age or older, Prostate 1 Imaging screen for pro
Slide 26: Building an Eco-System: Sonalleve MR-HIFU
26 NASDAQ: PROF | TSX: PRN BUILDING AN ECO -SY STEM CORPORATE PRESENTATION SO NALLEVE MR-HIFU Current Technology & Commercialization Strategy
Slide 27: CORPORATE PRESENTATION
27 NASDAQ: PROF | TSX: PRN • Uses the same MR imaging and thermographic technology as TULSA-PRO • Combines that with focused ultrasound from outside the body to treat disease • Suitable for therapies in the body cavity CORPORATE PRESENTATION • Currently 10 Sonalleve devices operational commercially
Slide 28: Sonalleve MR-HIFU System (V2)
Sonalleve MR-HIFU System (V2) 28 NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION Sonalleve tabletop connected to the scanner Compatible with Philips MRI
Slide 29: V2 Platform Technology: One System, Multiple Modes of Action
V2 Platform Technology: One System, Multiple Modes of Action and 29 Clinical Applications Mode of Action NASDAQ: PROF | TSX: PRN Clinical Applications Pediatric Care: Regulatory Approved Applications Primary treatment US Osteoid osteoma Ablation • Tissue Destruction FDA HDE approval • Thermal Necros
Slide 30: CORPORATE PRESENTATION
CORPORATE PRESENTATION NASDAQ: PROF | TSX: PRN 30
Slide 31: Paving the Way for the Future: iMRI Suite
Paving the Way for the Future: 31 iMRI Suite NASDAQ: PROF | TSX: PRN CORPORATE PRESENTATION Prostate Pancreas Adenomyosis Brain Cardiovascular Spine
Slide 32: In Summary
In Summary 32 Versatile, MRI-Guided Technologies NASDAQ: PROF | TSX: PRN TULSA-PRO technology for whole or partial gland ablative treatment of prostate tissue – malignant or benign Robust and Growing Clinical Evidence Over 70 peer-reviewed clinical publications, 200 presentations, and 7-year outcome
Profound Medical — Investor Presentation (November 2025) on 6ix